Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on August 30, 2006. The registrant is a Florida corporation headquartered in New York, New York. The report discloses a corporate governance event regarding the appointment of a new director.
Key Financial Metrics
The filing text does not provide any financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly informational regarding personnel changes.
Material Changes
The material change reported is the formal approval of David Sidransky, M.D. to serve as a director of Xenomics, Inc. on August 30, 2006. Dr. Sidransky had been previously appointed subject to this approval from Johns Hopkins University. He brings significant experience as the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and has served on advisory boards for companies such as MedImmune, Telik, Roche, and Amgen.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document focuses solely on the biographical qualifications and professional background of the newly approved director.
Investor Verification Checklist
- Verify the correct registrant name is Xenomics, Inc., not Cardiff Oncology, Inc.
- Confirm the effective date of Dr. Sidransky's directorship is August 30, 2006.
- Review Dr. Sidransky's existing board affiliations (Imclone Systems, Alfacell) for potential conflict of interest disclosures in other filings.
- Note that no financial performance data is included in this specific 8-K filing.